[Hemodynamic effects of the cold pressor test in patients with heart failure treated with beta blockers for a long

A V Mattioli1, G Bettelli, C Cappello

  • 1Cattedra di Malattie dell'Apparato Cardiovascolare, Università degli Studi, Modena.

Cardiologia (Rome, Italy)
|December 1, 1990
PubMed

Insights

Beta-blocker therapy may benefit patients with congestive heart failure (CHF) by improving cardiac function. This study found that atenolol attenuated sympathetic response in CHF patients, suggesting a mechanism for improved outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) is associated with reduced beta-adrenoceptor density and responsiveness.
  • Beta-blocker therapy has shown potential to improve clinical outcomes in select CHF patients.

Purpose of the Study:

  • To evaluate the sympathetic nervous system response in patients with CHF.
  • To assess the hemodynamic effects of the cold pressor test in CHF patients with and without beta-blocker treatment.

Main Methods:

  • Hemodynamic parameters (heart rate, blood pressure, cardiac index, etc.) were measured during the cold pressor test.
  • The study included 20 participants: 10 with CHF and 10 healthy volunteers, divided into four therapy groups.
  • Evaluated modifications in heart rate, mean arterial pressure, and systemic vascular resistance.

Main Results:

  • In healthy subjects, the cold pressor test induced expected hemodynamic changes.
  • In CHF patients not on beta-blockers, an increased heart rate, elevated systemic vascular resistance, and reduced cardiac index were observed.
  • Atenolol treatment attenuated the sympathetic response to the cold pressor test in CHF patients, with a trend towards increased cardiac index.

Conclusions:

  • Beta-blocker therapy, specifically with atenolol, appears to modulate sympathetic response in CHF.
  • The observed trend of increased cardiac index with atenolol treatment may explain its beneficial effects in selected CHF patients.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...